Novel approaches for the treatment of non-small cell lung cancer

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 14, 2001, Pages 45-49

  Bonomi, Philip ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 7 HYDROXYSTAUROSPORINE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BMS 2751911; BRYOSTATIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DOCETAXEL; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKING AGENT; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; LIPOXYGENASE INHIBITOR; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NAVELBINE; PACLITAXEL; PRINOMASTAT; PROTEIN KINASE C INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SULINDAC SULFONE; TANOMASTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DNA VECTOR; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH;

EID: 0034797210     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.27634     Document Type: Review

References (33)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Novel chemotherapy agents in the treatment of non-small cell lung cancer
3. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
4. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
5. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
6. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
7. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian lung cancer project
8. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial
9. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
10. Angiogenesis and non-small cell lung cancer
11. Matrix metalloproteinases: Biologic activity and clinical implications
12. Halting angiogenesis suppresses carcinoma cell invasion
13. A randomized phase 11 trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
14. Structure of the tyrosine kinase domain of the fibroblast factor receptor in complex with inhibitors
15. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
16. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
17. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale, and preliminary clinical results
18. Tyrosine kinase inhibitors in pre-clinical development
19. Intermittent oral ZD1829, a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a phase I study
20. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP 358,774 following platinum based chemotherapy in patients with advanced non-small cell lung cancer
21. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
22. A phase I trial of the farnesyltransferase inhibitor SCH66336: Evidence for biological and clinical activity
23. Effect of HER-2/neu expression on survival in early stage non-small cell lung cancer
24. Dysregulation of apoptosis in cancer
25. Cell cycle control and cancer
26. PTEN gene and integrin signaling in cancer
27. Protein kinase C targeting in antineoplastic treatment strategies
28. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy
29. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling
30. Mitochondrion as a novel target of anticancer chemotherapy
31. Retrovirusmediated wild-type p53 gene transfer to tumors of patients with large lung cancer
32. The effect of celecoxib, a cyclooxygenase-2 Inhibitor, in familial adenomatous polyposis
33. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction